Amphastar Pharmaceuticals (STU:29A) Cyclically Adjusted Revenue per Share: €9.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:29A Amphastar Pharmaceuticals Inc STU:29A
80 GF Score
Price €17.23
GF Value €42.55
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Cyclically Adjusted Revenue per Share?

Amphastar Pharmaceuticals STU:29A -1.57% 80 Cyclically Adjusted Revenue per Share is €9.13 as of Mar. 2026. GuruFocus rates STU:29A with a GF Score™ of 80/100 and a GF Value™ of €42.55 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amphastar Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was €3.187. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Amphastar Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 11.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amphastar Pharmaceuticals was -0.70% per year. The lowest was -0.70% per year. And the median was -0.70% per year.

As of today (2026-08-05), Amphastar Pharmaceuticals's current stock price is €17.23. Amphastar Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €9.13. Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 1.89.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amphastar Pharmaceuticals was 7.60. The lowest was 1.59. And the median was 3.44.


Amphastar Pharmaceuticals  (STU:29A) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.23/9.13
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amphastar Pharmaceuticals was 7.60. The lowest was 1.59. And the median was 3.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amphastar Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Amphastar Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 9.85 7.27 8.80 8.48

Amphastar Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.74 8.29 8.49 8.48 9.13

STU:29A vs ESPR, NIKA, BIOA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


STU:29A
80GF Score
Amphastar Pharmaceuticals Inc STU:29A
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amphastar Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.187/330.2130*330.2130
=3.187

Current CPI (Mar. 2026) = 330.2130.

Amphastar Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.317 241.018 1.804
201609 1.193 241.428 1.632
201612 1.183 241.432 1.618
201703 1.103 243.801 1.494
201706 1.212 244.955 1.634
201709 1.008 246.819 1.349
201712 1.035 246.524 1.386
201803 1.018 249.554 1.347
201806 1.306 251.989 1.711
201809 1.341 252.439 1.754
201812 1.704 251.233 2.240
201903 1.401 254.202 1.820
201906 1.402 256.143 1.807
201909 1.453 256.759 1.869
201912 1.524 256.974 1.958
202003 1.589 258.115 2.033
202006 1.630 257.797 2.088
202009 1.421 260.280 1.803
202012 1.586 260.474 2.011
202103 1.748 264.877 2.179
202106 1.703 271.696 2.070
202109 1.907 274.310 2.296
202112 2.137 278.802 2.531
202203 2.103 287.504 2.415
202206 2.194 296.311 2.445
202209 2.298 296.808 2.557
202212 2.465 296.797 2.743
202303 2.516 301.836 2.753
202306 2.533 305.109 2.741
202309 3.138 307.789 3.367
202312 3.081 306.746 3.317
202403 2.982 312.332 3.153
202406 3.256 314.175 3.422
202409 3.322 315.301 3.479
202412 3.472 315.605 3.633
202503 3.162 319.799 3.265
202506 3.142 322.561 3.217
202509 3.428 324.800 3.485
202512 3.315 324.054 3.378
202603 3.187 330.213 3.187

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €9.13 mean?
Amphastar Pharmaceuticals (STU:29A) has a Cyclically Adjusted Revenue per Share of €9.13 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amphastar Pharmaceuticals and its competitors.
Is Amphastar Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Amphastar Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €9.13. Overall, Amphastar Pharmaceuticals has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ESPR and NIKA?
Amphastar Pharmaceuticals' Cyclically Adjusted Revenue per Share of €9.13 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €9.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (STU:29A) is currently considered Significantly Undervalued. The stock's GF Value™ is €42.55, compared to a current price of €17.23 — trading 59.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €9.13. Amphastar Pharmaceuticals' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Amphastar Pharmaceuticals (STU:29A), the current Cyclically Adjusted Revenue per Share is €9.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (STU:29A) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of €17.23 is trading 59.5% below its estimated GF Value™ of €42.55. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:29A:

  • Cyclically Adjusted Revenue per Share: €9.13
  • GF Value™: €42.55 vs. price of €17.23 (59.5% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the STU:29A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amphastar Pharmaceuticals Business Description

Other Exchanges AMPH:USA
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
80GF Score

Get the complete analysis for STU:29A

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.23
Price
€42.55
GF Value